NU7441 (KU-57788)

Catalog No.S2638

Molecular Weight(MW): 413.49

NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits PI3K with IC50 of 5 μM in cell-free assays. It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage.

Cited by 86 Publications

Nature, 2019, 74(7779):571-574

PubMed: 31645724 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):396-410

PubMed: 30205044 ( click the link to review the publication )

Nat Biotechnol, 2017, 35(5):463-474

PubMed: 28319085 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5304

PubMed: 31757956 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1577

PubMed: 30952868 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3925

PubMed: 31477700 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2866

PubMed: 31253785 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(18):5608-5622

PubMed: 31266829 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32558

PubMed: 31283004 ( click the link to review the publication )

Oncogene, 2019, 38(14):2451-2463

PubMed: 30532030 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31480356 ( click the link to review the publication )

Br J Cancer, 2019, 121(7):600-610

PubMed: 31481733 ( click the link to review the publication )

FASEB J, 2019, 33(11):11668-11681

PubMed: 31348687 ( click the link to review the publication )

FASEB J, 2019, 33(6):6778-6788

PubMed: 30807703 ( click the link to review the publication )

PLoS Genet, 2019, 15(2):e1007925

PubMed: 30716077 ( click the link to review the publication )

J Environ Manage, 2019, 244:77-82

PubMed: 31108313 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(12):2457-2468

PubMed: 31551253 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz178

PubMed: 31388677 ( click the link to review the publication )

J Biol Chem, 2019, 294(8):2827-2838

PubMed: 30598506 ( click the link to review the publication )

Front Physiol, 2019, 10:616

PubMed: 31178753 ( click the link to review the publication )

BMC Pulm Med, 2019, 19(1-:165

PubMed: 31464599 ( click the link to review the publication )
Mol Biol Rep, 2019, 10.1007/s11033-019-04605-0

PubMed: 31020489 ( click the link to review the publication )

Mol Biol Rep, 2019, 10.1007/s11033-019-05105-x

PubMed: 31583565 ( click the link to review the publication )

Mol Med Rep, 2019, 20(4):3609-3616

PubMed: 31485633 ( click the link to review the publication )

FEBS Open Bio, 2019, 9(7):1315-1326

PubMed: 31141305 ( click the link to review the publication )

Cell Res, 2018, 28(7):756-770

PubMed: 29844578 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5351

PubMed: 30559436 ( click the link to review the publication )

Cell Rep, 2018, 24(4):987-1000

PubMed: 30044993 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):931

PubMed: 30209297 ( click the link to review the publication )

FASEB J, 2018, 32(4):1818-1829

PubMed: 29162700 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(23):4024-4035

PubMed: 30107443 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):428-438

PubMed: 29222170 ( click the link to review the publication )

DNA Repair (Amst), 2018, 68:68-74

PubMed: 30017059 ( click the link to review the publication )

Mol Biol Cell, 2018, 29(15):1786-1797

PubMed: 29897835 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9685

PubMed: 29946146 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14421

PubMed: 30258062 ( click the link to review the publication )

Biochem Biophys Rep, 2018, 16:115-121

PubMed: 30417129 ( click the link to review the publication )

Oncotarget, 2018, 9(9):8560-8572

PubMed: 29492217 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(1):244-254

PubMed: 28069995 ( click the link to review the publication )

Cancer Immunol Res, 2017, 5(9):790-803

PubMed: 28775208 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4567-4578

PubMed: 28698210 ( click the link to review the publication )

Cancer Res, 2017, 77(18):4745-4754

PubMed: 28754673 ( click the link to review the publication )

J Biol Chem, 2017, 292(30):12424-12435

PubMed: 28592488 ( click the link to review the publication )

Mol Biol Cell, 2017, 28(26):3756-3772

PubMed: 29074567 ( click the link to review the publication )
Int J Biochem Cell Biol, 2017, 92:164-172

PubMed: 28827033 ( click the link to review the publication )

Radiat Res, 2017, 188(6):597-604

PubMed: 28952912 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181608

PubMed: 28750002 ( click the link to review the publication )

DNA Repair (Amst), 2017, 54:30-39

PubMed: 28448822 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90037-90049

PubMed: 29163809 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(11):1196-1207

PubMed: 27723717 ( click the link to review the publication )

blood, 2016, 10.1182/blood-2016-02-700328

PubMed: ( click the link to review the publication )

Blood, 2016, 128(4):574-83

PubMed: 27235137 ( click the link to review the publication )

Nat Commun, 2016, 7:12880

PubMed: 27634057 ( click the link to review the publication )

Oncogene, 2016, 35(5):577-586

PubMed: 25893305 ( click the link to review the publication )

Cancer Lett, 2016, 383(1):41-52

PubMed: 27693461 ( click the link to review the publication )

Cell Death Dis, 2016, 7(7):e2316

PubMed: 27468692 ( click the link to review the publication )

Cell Cycle, 2016, 15(1):84-94

PubMed: 26771713 ( click the link to review the publication )

PLoS One, 2016, 11(12):e0167454

PubMed: 27907109 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0163049

PubMed: 27643854 ( click the link to review the publication )

Oncotarget, 2016, 7(38):60807-60822

PubMed: 27602502 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65504-65513

PubMed: 27602767 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(9):1158-68

PubMed: 26237645 ( click the link to review the publication )

Leukemia, 2015, 29(5):1133-42

PubMed: 25371178 ( click the link to review the publication )

Genome Med, 2015, 10.1186/s13073-015-0215-6

PubMed: 26307031 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: 25232030 ( click the link to review the publication )

Anticancer Res, 2015, 35(7):3829-38

PubMed: 26124328 ( click the link to review the publication )
Nucleic Acids Res, 2014, 42(12):7776-92

PubMed: 24906880 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(9):5616-32

PubMed: 24598253 ( click the link to review the publication )

Genes Dev, 2014, 28(8):875-87

PubMed: 24700029 ( click the link to review the publication )

Cancer Res, 2014, 74(16):4282-94

PubMed: 24894717 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.268

PubMed: 25132265 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(5):1160-71

PubMed: 24568369 ( click the link to review the publication )

Toxicol Sci, 2014, 10.1093/toxsci/kfu207

PubMed: 25288669 ( click the link to review the publication )

Biosci Rep, 2014, 34(3)

PubMed: 24844881 ( click the link to review the publication )

Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2014,

PubMed: ( click the link to review the publication )

Uppsala University, 2014, Department of Radiology

PubMed: ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(22):10157-69

PubMed: 24021630 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(7):4080-92

PubMed: 23449221 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(15):7378-86

PubMed: 23775790 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2013, 88(2):385-94

PubMed: 24411611 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA-PK Inhibitors

Biological Activity

Description

Targets

DNA-PK ^[1]
(Cell-free assay)

14 nM

In vitro

NU7441 increases the persistence of γH2AX foci after ionizing radiation–induced or etoposide-induced DNA damage. NU7441 (0.5 μM or 1 μM) appreciably increases G2-M accumulation induced by ionizing radiation, etoposide, and doxorubicin in both SW620 and LoVo cells. ^[2] NU7441 causes persistence of doxorubicin- and ionising radiation-induced DNA double-strand break and also slightly decreases homologous recombination activity DNA-PK-proficient M059-Fus-1 and DNA-PK-deficient M059 J human tumour cells. ^[3] NU7441 inhibits UV-induced RPA p34 hyperphosphorylation in a dose-dependent manner both in cells lacking and cells expressing polymerase η. ^[4] NU7441 increases levels of fludarabine-induced γH2AX foci and correspondingly decreased fludarabine-induced cell death in chronic lymphocytic leukemia cells. ^[5] NU7441 also inhibits mitoxantrone-induced DNA-PKcs autophosphorylation and repair in chronic lymphocytic leukemia cells. ^[6] It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage^[7].

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
NCI-H1770	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTEfoQ4UUN3ME2wMlAzOTR\|IN88US=>	MmqyV2FPT0WU
A172	NGXWU4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\nXYNvUUN3ME2wMlE2OzF4IN88US=>	M4nqPXNCVkeHUh?=
NCI-H526	MlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEToUpVKSzVyPUCuNlg1ODdizszN	M1PqOnNCVkeHUh?=
HDLM-2	M4DvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;sUmdKSzVyPUCuN\|I{PDVizszN	MVTTRW5ITVJ?
HuO-3N1	MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTBwNE[2N\|Yh\|ryP	NIXIR2pUSU6JRWK=
NCI-SNU-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVu3SGg6UUN3ME2wMlYxQTl2IN88US=>	M121dXNCVkeHUh?=
SK-N-AS	M3zYeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljuTWM2OD1yLk[yNlE3KM7:TR?=	MlfiV2FPT0WU
LoVo	NWPPW\|R1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnu2TWM2OD1yLki2O\|Q6KM7:TR?=	M2DQ[nNCVkeHUh?=
LAMA-84	NX7GU2RZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\yWpVWUUN3ME2wMlk5QDN\|IN88US=>	M3rQbHNCVkeHUh?=
CTB-1	MmLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHrTWM2OD1zLkGxOVQ3KM7:TR?=	NV\H[mlKW0GQR1XS
KP-N-YS	MorOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHNNGZtUUN3ME2xMlE1OjNzIN88US=>	NWHzfHM1W0GQR1XS
HH	NUC0VJQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV76WINRUUN3ME2xMlE5ODl\|IN88US=>	MoqyV2FPT0WU
CHL-1	MnGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLzTlN4UUN3ME2xMlIyOzZ6IN88US=>	MofKV2FPT0WU
NB7	NWXNXoRxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvJNpUzUUN3ME2xMlI1PzR3IN88US=>	NIXH[3RUSU6JRWK=
HL-60	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF70ZpNKSzVyPUGuN\|gyQSEQvF2=	MVrTRW5ITVJ?
639-V	NXu2R4NuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTFwNESxNlgh\|ryP	NXOwd3E1W0GQR1XS
NCI-H1793	MnfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTFwNEW4OEDPxE1?	NGDI[2tUSU6JRWK=
NEC8	MlrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fTfmlEPTB;MT61OVM2KM7:TR?=	NGXFcVZUSU6JRWK=
PA-1	M4nYdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfrTWM2OD1zLkW4Nlk1KM7:TR?=	MkjiV2FPT0WU
D-423MG	NHzKS3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jBNmlEPTB;MT62PVM3OSEQvF2=	MkTPV2FPT0WU
NCI-H292	M2PhNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2i0TWlEPTB;MT63OFAyOyEQvF2=	NXvkWG57W0GQR1XS
SK-MEL-1	NYnlXWp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37KemlEPTB;MT63PVQ4QSEQvF2=	MV\TRW5ITVJ?
LB2241-RCC	NE\XUlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2r3VWlEPTB;Mj6xOFE1PiEQvF2=	M13iXXNCVkeHUh?=
SK-MEL-3	NITKOIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTJwMU[0PUDPxE1?	MoLmV2FPT0WU
MHH-PREB-1	NVezcJRuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlezTWM2OD1{LkG2OlA6KM7:TR?=	MX\TRW5ITVJ?
BFTC-905	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTJwMU[2PFch\|ryP	NHLnXHBUSU6JRWK=
Ramos-2G6-4C10	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPXZ3RKSzVyPUKuNVk6ODlizszN	NHPKOpJUSU6JRWK=
G-361	MnvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPUWldKSzVyPUKuNlE3QCEQvF2=	NHrkRoJUSU6JRWK=
MOLT-4	NESyTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTJwMkG4PFgh\|ryP	M4TUPHNCVkeHUh?=
DEL	NHSwVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjiOYc4UUN3ME2yMlM2PTZ2IN88US=>	M1jnT3NCVkeHUh?=
MV-4-11	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nmfWlEPTB;Mj6zO\|M6KM7:TR?=	NFezVpVUSU6JRWK=
SK-NEP-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTJwM{i3PFMh\|ryP	MWnTRW5ITVJ?
RS4-11	M1;icGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTJwNU[wNlMh\|ryP	NFr2[IxUSU6JRWK=
HuH-7	Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWi2SYFwUUN3ME2yMlU3PzB{IN88US=>	NVzuS4ZWW0GQR1XS
A101D	MmXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPBbVhNUUN3ME2yMlYyOzN6IN88US=>	MX3TRW5ITVJ?
KG-1	NU\zT3g2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTJwNke5NlQh\|ryP	MVXTRW5ITVJ?
KALS-1	M2LWdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zDfWlEPTB;Mj62PVY{OyEQvF2=	Mo[wV2FPT0WU
VMRC-RCZ	NU\IVIlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTJwN{ezNlgh\|ryP	NEPmeJhUSU6JRWK=
SK-UT-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jFOmlEPTB;Mz6xOVMyKM7:TR?=	Mm\kV2FPT0WU
SW962	NHHEbppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\QWGlEPTB;Mz6yNFM2OiEQvF2=	NI\GT4RUSU6JRWK=
DBTRG-05MG	MoK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTNwMkiwPFUh\|ryP	NWD0[odvW0GQR1XS
PANC-08-13	NYK1SndTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkS4TWM2OD1\|LkSxNlc5KM7:TR?=	MU\TRW5ITVJ?
QIMR-WIL	MmP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2O5VWlEPTB;Mz60NVM1OSEQvF2=	NIrtS2ZUSU6JRWK=
SK-MEL-30	NHW3TIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTNwNEK1PVgh\|ryP	NIXvOYtUSU6JRWK=
697	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEn0RllKSzVyPUOuOFQ6QTNizszN	MkDuV2FPT0WU
NY	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\tTWM2OD1\|LkS1NFIzKM7:TR?=	NHrRVFRUSU6JRWK=
ES7	M3n4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTNwNE[3Nlkh\|ryP	NYHPO5JLW0GQR1XS
JVM-3	M13Qd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTNwNEiwO\|ch\|ryP	M1;WcnNCVkeHUh?=
U031	NVz2fWd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH76V4VKSzVyPUOuOVk{PjhizszN	NWPjN2N6W0GQR1XS
BHT-101	NULSemU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjBe3dKSzVyPUOuOVk6QDVizszN	M3TRSnNCVkeHUh?=
8305C	NVzNUo9XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTNwNkG3N\|Yh\|ryP	MlHHV2FPT0WU
MG-63	NXu0SVNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3rTYd2UUN3ME2zMlYzPjd4IN88US=>	MlriV2FPT0WU
NOS-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGn1eZRKSzVyPUOuOlU{OTJizszN	Mmj1V2FPT0WU
YH-13	MoX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTNwOEexPFkh\|ryP	M1;RU3NCVkeHUh?=
LXF-289	NYnIXJY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2m3[WlEPTB;Mz65NVA1OSEQvF2=	MlPuV2FPT0WU
GOTO	M3yw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjVTWM2OD1\|LkmxOFkh\|ryP	MYjTRW5ITVJ?
EKVX	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\p[XlKSzVyPUSuNlI2OjRizszN	NG\ZV\|hUSU6JRWK=
CAL-51	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGf6ZYRKSzVyPUSuNlQ5PTRizszN	MlfFV2FPT0WU
AN3-CA	NGDIXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTRwMkW4NVMh\|ryP	MmXhV2FPT0WU
IA-LM	NWrQVHRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHl[VBnUUN3ME20MlI4QTN3IN88US=>	NYK2XlZVW0GQR1XS
KU-19-19	Mnn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLjdJFUUUN3ME20MlMzQTJzIN88US=>	M2HZN3NCVkeHUh?=
A704	NHq5cHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTRwNEC4PFgh\|ryP	M2XEOXNCVkeHUh?=
RH-18	MkDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnuxTWM2OD12LkS0PVU{KM7:TR?=	MXfTRW5ITVJ?
IST-MEL1	NEHCRnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTRwNUiyOlMh\|ryP	MnLlV2FPT0WU
LU-134-A	NU\PXnNzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvVS2hKSzVyPUSuOVk3QDVizszN	NVOxRXc3W0GQR1XS
SF126	NInpfGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fpWmlEPTB;ND62NFcyPSEQvF2=	MV3TRW5ITVJ?
EFO-27	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTRwNk[1NlUh\|ryP	MnWyV2FPT0WU
SN12C	NYTGTXc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX2xXmFHUUN3ME20MlcyQDl6IN88US=>	NVzublNXW0GQR1XS
L-363	NECyO3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4D1eWlEPTB;ND63O\|EyPiEQvF2=	NH6xR3RUSU6JRWK=
MEL-HO	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzjTWM2OD12Lke3PVg6KM7:TR?=	NVO2fY5zW0GQR1XS
TYK-nu	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHu2O3ZKSzVyPUSuPFAyOjhizszN	NUfYWohrW0GQR1XS
MDA-MB-415	NF;o[4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTVwMECzNVQh\|ryP	MVLTRW5ITVJ?
HCC70	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTVwMEO5N\|kh\|ryP	MkjBV2FPT0WU
IGROV-1	M4DoWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTVwMkWyPVIh\|ryP	MXLTRW5ITVJ?
NCI-H1355	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTVwMkm2JO69VQ>?	MVnTRW5ITVJ?
23132-87	NIDEcWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPrTWM2OD13LkOyNFI1KM7:TR?=	MnjEV2FPT0WU
NB69	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfkTWM2OD13LkOyOFIh\|ryP	NXmxcGcxW0GQR1XS
HSC-2	NVPSRXBbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTVwNEG3O\|Mh\|ryP	NHf1cHNUSU6JRWK=
KYSE-410	NITGbIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4P2d2lEPTB;NT60O\|Y{PiEQvF2=	MXnTRW5ITVJ?
GCIY	NX\Fd5ZzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3jeHhDUUN3ME21MlUyOzd6IN88US=>	NUe3fYs3W0GQR1XS
A427	MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\OZ3JZUUN3ME21MlU{PjZzIN88US=>	M4HRe3NCVkeHUh?=
ChaGo-K-1	NX\sdXNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTvTWM2OD13LkW2OVk6KM7:TR?=	Mm\SV2FPT0WU
PFSK-1	MnfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHzUGZVUUN3ME21MlYzOTl2IN88US=>	MmfzV2FPT0WU
MLMA	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3nTWM2OD13LkizOlA3KM7:TR?=	MXrTRW5ITVJ?
RVH-421	NEDLRo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTZwMEezN\|gh\|ryP	MU\TRW5ITVJ?
LB1047-RCC	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4T2U2lEPTB;Nj6xO\|UzOiEQvF2=	NUTDO5J2W0GQR1XS
MHH-NB-11	MmryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrETWM2OD14LkOyO\|IyKM7:TR?=	MoPZV2FPT0WU
J-RT3-T3-5	M1XLR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fPUWlEPTB;Nj62N\|I6OSEQvF2=	MnvpV2FPT0WU
UM-UC-3	NUHJXI9PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHMTWM2OD14Lk[0N\|M1KM7:TR?=	NY\XNmI2W0GQR1XS
IST-SL1	Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjZfmxKSzVyPU[uOlk{PjlizszN	Mn;wV2FPT0WU
NB14	MmPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPuTWM2OD14Lke5O\|YyKM7:TR?=	NWDOVXhvW0GQR1XS
NBsusSR	MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTSVlZsUUN3ME22MlgzPTB{IN88US=>	M2Cxb3NCVkeHUh?=
D-263MG	NHHpU5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfvUG9jUUN3ME22MlkyODZ6IN88US=>	M1:4TXNCVkeHUh?=
NCI-H2347	MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFyyWZVKSzVyPU[uPVMzOTNizszN	M2nwWXNCVkeHUh?=
ES8	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTZwOUe1PFgh\|ryP	NWrEXYRTW0GQR1XS
786-0	MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\qUZlWUUN3ME23MlA6Pzh4IN88US=>	Ml;5V2FPT0WU
EPLC-272H	MlrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFj5NWRKSzVyPUeuNVYzPDZizszN	MmH0V2FPT0WU
CAPAN-1	NVnx[Wx5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LVemlEPTB;Nz6yOFM2QSEQvF2=	MnXnV2FPT0WU
NCI-H82	NE\KNItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPxcXNIUUN3ME23MlI3PjV7IN88US=>	MojmV2FPT0WU
G-402	M3joWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHofIlKSzVyPUeuN\|AxPTFizszN	NGG1fo5USU6JRWK=
SW982	M1TzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nlemlEPTB;Nz6zNFIxOyEQvF2=	MVHTRW5ITVJ?
OVCAR-4	NFftXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrnTWM2OD15LkOxN\|I5KM7:TR?=	NUPZVYNGW0GQR1XS
KARPAS-299	NXe2PXNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXVTWM2OD15LkOyOlIzKM7:TR?=	NVj3NWNpW0GQR1XS
MIA-PaCa-2	NULofGZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnj[HVKSzVyPUeuN\|Y5OjNizszN	NF\PbXVUSU6JRWK=
AU565	MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTdwNUm4N\|Mh\|ryP	MV7TRW5ITVJ?
GAMG	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFv6So1KSzVyPUeuOlQyOzFizszN	Ml\iV2FPT0WU
HuO9	NXrrOWNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTdwN{G3OFMh\|ryP	MoDWV2FPT0WU
ACN	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTdwN{SzN{DPxE1?	MnG5V2FPT0WU
RO82-W-1	NVu4VItST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4Xh[mlEPTB;Nz63OFU{OyEQvF2=	NF:5PZFUSU6JRWK=
NKM-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELsOGFKSzVyPUeuO\|Q6PTVizszN	NX7qNnBIW0GQR1XS
CAL-12T	M37ZUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoToTWM2OD15Lkm0N\|UzKM7:TR?=	MXHTRW5ITVJ?
FADU	NFS1XZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTsTWM2OD16LkCzOlU1KM7:TR?=	M3P0TXNCVkeHUh?=
NCI-H28	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MomzTWM2OD16LkG2PVYzKM7:TR?=	MVLTRW5ITVJ?
LCLC-97TM1	NIr4PGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXNToIyUUN3ME24MlIyOTJ{IN88US=>	NEXySHRUSU6JRWK=
CHP-134	NHLvbHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjhbllLUUN3ME24MlI1OTh3IN88US=>	MWXTRW5ITVJ?
HT-1080	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fXT2lEPTB;OD6yOVA6OyEQvF2=	M3i1dHNCVkeHUh?=
PC-3	NHHGXI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXW4XXhuUUN3ME24MlI4Ozl{IN88US=>	MW\TRW5ITVJ?
SNU-449	NF\aS3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHf3VmRKSzVyPUiuNlc6OyEQvF2=	MnPPV2FPT0WU
VA-ES-BJ	M3\JT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYqxWnprUUN3ME24MlM1Pjh4IN88US=>	MULTRW5ITVJ?
HT	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRThwM{[0PUDPxE1?	NYjBVZR6W0GQR1XS
HOS	NFvINYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXi3dpZbUUN3ME24MlM4PTh7IN88US=>	M1PEb3NCVkeHUh?=
KNS-62	Mn7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRThwM{e3OlIh\|ryP	M1PKZ3NCVkeHUh?=
OAW-42	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jvPGlEPTB;OD65OVk3PCEQvF2=	MoL6V2FPT0WU
A549	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjxdmpDUUN3ME25MlA6PjF{IN88US=>	NH\sPFVUSU6JRWK=
CAKI-1	M{G3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTlwMU[2NUDPxE1?	NVjFVW9XW0GQR1XS
HCC1937	M{DlU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3ntVmlEPTB;OT62PVg3PSEQvF2=	M{XadHNCVkeHUh?=
GI-ME-N	NYW3Uop4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXZd3pkUUN3ME25MlcxOTN5IN88US=>	NHzuS\|VUSU6JRWK=
DU-4475	MmO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTlwOU[5N\|kh\|ryP	MlPsV2FPT0WU
EM-2	NVe5Vm1pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoC3TWM2OD1zMD6yOFI3KM7:TR?=	NGrwZ4pUSU6JRWK=
NCI-H1755	NWLUe25sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHZTWM2OD1zMD6yOFI5KM7:TR?=	MmXLV2FPT0WU
NCI-H1437	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;BdnJKSzVyPUGwMlU4OjVizszN	MlS5V2FPT0WU
VM-CUB-1	NXfNfmVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXn5dJM{UUN3ME2xNE43OTZ2IN88US=>	NYHYOml5W0GQR1XS
A2058	M3;FW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPsT2hKSzVyPUGwMlY1ODRizszN	NXvSS4tbW0GQR1XS
BPH-1	MknZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTFyLkexOFUh\|ryP	NHrF[VNUSU6JRWK=
NB5	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTFyLke1OVkh\|ryP	NID6WmJUSU6JRWK=
G-401	M3Pkc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTFyLke2NlYh\|ryP	M33BPXNCVkeHUh?=
CAL-72	MlTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTFyLkiwPVQh\|ryP	MVXTRW5ITVJ?
SK-MEL-28	Mlf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGX2UGlKSzVyPUGwMlgzODJizszN	MlexV2FPT0WU
C32	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGC4WHpKSzVyPUGwMlg{PDdizszN	M{fwcHNCVkeHUh?=
NCI-H1155	NWrTO5ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\EOmlEPTB;MUCuPFM4PiEQvF2=	M4roXHNCVkeHUh?=
BB49-HNC	M1i0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHaSmRFUUN3ME2xNE45PTh4IN88US=>	NGjzTXdUSU6JRWK=
GMS-10	NUTYc2ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnXXGZCUUN3ME2xNE45QTdzIN88US=>	M4j6R3NCVkeHUh?=
K5	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXWTWM2OD1zMD65NFcyKM7:TR?=	MXPTRW5ITVJ?
OS-RC-2	MlzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHZWFY1UUN3ME2xNU4xPTV7IN88US=>	M1LrW3NCVkeHUh?=
HTC-C3	Mo[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnOdXdmUUN3ME2xNU4xPzF2IN88US=>	NG\mVlZUSU6JRWK=
LB996-RCC	M{jERWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTFzLkC3NlMh\|ryP	M3X1UHNCVkeHUh?=
NCI-H1563	MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLtTWM2OD1zMT6xNFEyKM7:TR?=	MYXTRW5ITVJ?
CAL-54	MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInNUZRKSzVyPUGxMlQ5OTFizszN	MXzTRW5ITVJ?
WM-115	NGPjZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXQTFlJUUN3ME2xNU43QDJ2IN88US=>	Mo\nV2FPT0WU
COLO-684	NGr3Z5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPKTWM2OD1zMT63NlY4KM7:TR?=	MW\TRW5ITVJ?
HOP-62	NXHDXppLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn2wTWM2OD1zMT63OVA5KM7:TR?=	MXnTRW5ITVJ?
NCI-H650	Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnSyTWM2OD1zMT64PVYyKM7:TR?=	M3PtPHNCVkeHUh?=
TE-11	M2TIe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXkTWM2OD1zMT65N\|E2KM7:TR?=	MXvTRW5ITVJ?
COLO-679	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjNTWM2OD1zMT65OFYh\|ryP	MUXTRW5ITVJ?
FTC-133	M2q2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTF{LkCwO\|Yh\|ryP	NGLneYlUSU6JRWK=
D-283MED	NIqwWlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPIenpKSzVyPUGyMlA2PjlizszN	NXi3XmtlW0GQR1XS
SK-PN-DW	M3TPUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWH1VGpZUUN3ME2xNk4yQTB{IN88US=>	MVjTRW5ITVJ?
BALL-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTF{LkK2OlIh\|ryP	MVrTRW5ITVJ?
GT3TKB	M2j6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7tRodKSzVyPUGyMlMxPzRizszN	NVP5bIx2W0GQR1XS
HOP-92	NHjCc2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HTUGlEPTB;MUKuOVI{OyEQvF2=	NXrlUolpW0GQR1XS
M14	NVe3bG5MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfvTWM2OD1zMz6wN\|M2KM7:TR?=	MYHTRW5ITVJ?
SKG-IIIa	M3jabWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTF\|LkC1OVQh\|ryP	MUfTRW5ITVJ?
Becker	M4TCO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLxNVNGUUN3ME2xN{4xPThizszN	NGCze2RUSU6JRWK=
ES5	Mnf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrB[2Z4UUN3ME2xN{4yOzV4IN88US=>	MkXqV2FPT0WU
NCI-H2030	NEK1NmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTF\|LkKwOlIh\|ryP	MmjaV2FPT0WU
SNU-423	NVnZUmhTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTF\|LkO4NUDPxE1?	NFflSYVUSU6JRWK=
CP50-MEL-B	Ml\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTTTWM2OD1zMz62NlMzKM7:TR?=	NV\wfVFIW0GQR1XS
NCI-H1092	MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTF\|Lke0O\|Uh\|ryP	MorqV2FPT0WU
8-MG-BA	MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPJTWM2OD1zMz63OVE{KM7:TR?=	MYTTRW5ITVJ?
CAL-27	NVOzUmNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoTQTWM2OD1zND6wO\|I4KM7:TR?=	NILLVGRUSU6JRWK=
AGS	M2XYV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIL2R21KSzVyPUG0MlE{OTlizszN	NYHCZ3BwW0GQR1XS
MZ2-MEL	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;tfnpmUUN3ME2xOE4yPDh6IN88US=>	MYrTRW5ITVJ?
BFTC-909	NF7qeXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTVTWM2OD1zND61NFU2KM7:TR?=	NVzoTFM{W0GQR1XS
D-566MG	NHv2dm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTF2Lke3NFYh\|ryP	NYnhV5BLW0GQR1XS
MZ7-mel	M3jLV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HXUGlEPTB;MUWuNVA3PyEQvF2=	NVPne5F4W0GQR1XS
TE-5	NWHK[5RJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7CTY4zUUN3ME2xOU4zOzN\|IN88US=>	NFnicXFUSU6JRWK=
647-V	NHTIV45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2i5TWlEPTB;MUWuNlcxPSEQvF2=	NWLEdFBkW0GQR1XS
DMS-114	M4nZdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfpdVFKSzVyPUG1MlMzQTFizszN	M1\1VXNCVkeHUh?=
ME-180	NFX5bIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7nRplUUUN3ME2xOU41Pzh\|IN88US=>	NHfuS3VUSU6JRWK=
MS-1	NYLseYxKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml24TWM2OD1zNT61OlI{KM7:TR?=	NEiyWIhUSU6JRWK=
NUGC-3	M3y4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjzSnhKSzVyPUG1MlYzPDVizszN	MnPEV2FPT0WU
GB-1	M1TD[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjHdYViUUN3ME2xOU43PDN5IN88US=>	MXTTRW5ITVJ?
LOXIMVI	NX[wUYl5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTF3Lki5NVkh\|ryP	MX3TRW5ITVJ?
NCI-H1304	NGDuOnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTmTWM2OD1zNT64PVI5KM7:TR?=	M1HifnNCVkeHUh?=
KURAMOCHI	Mn3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfhSHdWUUN3ME2xOU46PzFizszN	NXfRR2I6W0GQR1XS
SW1783	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XHc2lEPTB;MU[uNFk6OyEQvF2=	NGDh[lJUSU6JRWK=
EGI-1	NFPIXJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmL6TWM2OD1zNj61N\|Y2KM7:TR?=	Mk\tV2FPT0WU
KGN	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\sR4JKSzVyPUG2MlU2QDZizszN	NHPTNoxUSU6JRWK=
PANC-03-27	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTF4Lke2OlIh\|ryP	NWe0WXU3W0GQR1XS
RH-1	NE\Lb2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LXUGlEPTB;MU[uPFI2KM7:TR?=	NWSydpl3W0GQR1XS
HT-1376	NHTYT2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7RTWM2OD1zNj64OFQ3KM7:TR?=	MVTTRW5ITVJ?
ZR-75-30	NUnUU3BmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\WTWM2OD1zNj65N\|YyKM7:TR?=	NFX2OGtUSU6JRWK=
TI-73	MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXmXJVjUUN3ME2xOk46PDB6IN88US=>	MWPTRW5ITVJ?
TK10	NUXQRWhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DXTWlEPTB;MUeuNFA4QSEQvF2=	M3nLenNCVkeHUh?=
SW684	NVTu[3JZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTmTWM2OD1zNz6wNVU1KM7:TR?=	M4XwZ3NCVkeHUh?=
RPMI-8866	NWPkRYE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvuWY9KSzVyPUG3MlA3QTlizszN	MmD1V2FPT0WU
LNCaP-Clone-FGC	NYLDT\|d2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPNTWM2OD1zNz61NlAyKM7:TR?=	M2H3VnNCVkeHUh?=
NCI-H2291	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnvTWM2OD1zOD60N\|Q2KM7:TR?=	MnzGV2FPT0WU
T47D	NYjIOI1lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELZNINKSzVyPUG4MlQ5QCEQvF2=	NFXUfplUSU6JRWK=
A204	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF64NldKSzVyPUG4MlU1PTJizszN	M33CfHNCVkeHUh?=
HT-144	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDJT4tKSzVyPUG4Mlc1OjdizszN	MUTTRW5ITVJ?
MDA-MB-361	M2fqNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4P1fmlEPTB;MUmuNFcyPCEQvF2=	M4jEWXNCVkeHUh?=
HCC1806	NEfEbWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTpTWM2OD1zOT6xOVkyKM7:TR?=	MUDTRW5ITVJ?
NCI-H596	NVS4Z2FMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17WO2lEPTB;MUmuOlM6OSEQvF2=	NGTwVWVUSU6JRWK=
K-562	NXTaZoR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXwTWM2OD1zOT64PVI3KM7:TR?=	MWDTRW5ITVJ?
D-336MG	Mmi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWS1eGNRUUN3ME2xPU46OzJ{IN88US=>	MYDTRW5ITVJ?
SK-MEL-2	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTtTWM2OD1{MD6xOVU6KM7:TR?=	NXLGcZZbW0GQR1XS
HEC-1	MoS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DqSGlEPTB;MkCuOFk4QCEQvF2=	M13CXHNCVkeHUh?=
EW-13	NYK3dXp[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXv3eYJpUUN3ME2yNE42PDR\|IN88US=>	M2DnXHNCVkeHUh?=
Hs-578-T	NGLZ[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGL0SpZKSzVyPUKwMlU2QDNizszN	M1\aV3NCVkeHUh?=
SJSA-1	NVfYVG1zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTJyLkW2PFgh\|ryP	MoXWV2FPT0WU
RCC10RGB	M3qwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Moj1TWM2OD1{MD62O\|E6KM7:TR?=	NYmybGlTW0GQR1XS
LAN-6	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7QNlJKSzVyPUKxMlA{QTZizszN	NEPsO4lUSU6JRWK=
NCI-H1048	M1vJXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWK2Vo1lUUN3ME2yNU4zOjV6IN88US=>	MWjTRW5ITVJ?
CW-2	M1vnOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLLVXNKSzVyPUKxMlI4ODVizszN	Ml70V2FPT0WU
HCC2157	NWXmdm9LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3HTWM2OD1{MT6zOkDPxE1?	M{HMTXNCVkeHUh?=
EW-22	NY[zdnBFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPr[Wc4UUN3ME2yNU4{PzZizszN	NXzXRno5W0GQR1XS
A253	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTJzLkS0PFEh\|ryP	NV32d\|NnW0GQR1XS
BE-13	MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvUfZFKSzVyPUKxMlYyOTNizszN	NHj0RVlUSU6JRWK=
KINGS-1	NVTHOItwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\RNWpKSzVyPUKxMlY{OTZizszN	MY\TRW5ITVJ?
ETK-1	NFvuOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUG3dVlPUUN3ME2yNU45OTV{IN88US=>	MXzTRW5ITVJ?
NCI-H2452	NEHYR2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTJzLki2OFch\|ryP	NEXRN29USU6JRWK=
HPAF-II	M1;yNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nM[mlEPTB;MkGuPFkzOyEQvF2=	NXviZ3l3W0GQR1XS
D-542MG	NUXNcFg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV7JR\|UxRTJzLkmwOlkh\|ryP	MWDTRW5ITVJ?
NCI-H630	NIXNb\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjIWXhwUUN3ME2yNk4xOjl4IN88US=>	M330SnNCVkeHUh?=
TGBC11TKB	NILKfIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHUUIpKSzVyPUKyMlA1QSEQvF2=	M{Tvd3NCVkeHUh?=
BCPAP	MnTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3v3[WlEPTB;MkKuOlEyKM7:TR?=	NFi1bGtUSU6JRWK=
HLE	NV;uc5hjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zMd2lEPTB;MkKuOlk4KM7:TR?=	NFjmemhUSU6JRWK=
NCI-H727	M3XQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTJ{LkezOUDPxE1?	M4P1VXNCVkeHUh?=
RD	NInSVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XwZWlEPTB;MkKuO\|UyQCEQvF2=	NX;DemgzW0GQR1XS
NCI-H522	Ml3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vJXmlEPTB;MkKuPFQ{OSEQvF2=	Mn;xV2FPT0WU
CGTH-W-1	NU\RZYlrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHObpliUUN3ME2yN{4xPjRzIN88US=>	MVvTRW5ITVJ?
SK-LU-1	MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PlSmlEPTB;MkOuOFY5OyEQvF2=	MmWzV2FPT0WU
BB65-RCC	M1rMVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7OTHBvUUN3ME2yN{44QDZ\|IN88US=>	NEjrdppUSU6JRWK=
HSC-3	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;UbI9KSzVyPUKzMlg2OjdizszN	MoWxV2FPT0WU
SK-MES-1	NX3wdlZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\UTWM2OD1{ND6wNVYyKM7:TR?=	MoO1V2FPT0WU
DB	NFPTS\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnZU2VKSzVyPUK0MlExOjhizszN	NIC4VJJUSU6JRWK=
HO-1-N-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{O3WWlEPTB;MkSuN\|A6OyEQvF2=	M{\ZUHNCVkeHUh?=
MKN1	M1LTVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTJ2Lk[4JO69VQ>?	M{HM[XNCVkeHUh?=
MN-60	M3TIR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXYUIhKSzVyPUK0Mlg2OTlizszN	MknWV2FPT0WU
8505C	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTJ3LkG4OFUh\|ryP	NEDRZoRUSU6JRWK=
COLO-320-HSR	M4n4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HHOmlEPTB;MkWuNlIxQCEQvF2=	M1;5[XNCVkeHUh?=
BB30-HNC	NWfTdY9XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTJ3LkK0PFMh\|ryP	MXvTRW5ITVJ?
KM12	MofzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTJ3LkW4NFch\|ryP	MnHaV2FPT0WU
NB13	Mli5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTJ3LkW4PVgh\|ryP	MXPTRW5ITVJ?
HCC2998	NWi3Z5BKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mkm1TWM2OD1{Nj6wNlg{KM7:TR?=	MYTTRW5ITVJ?
U-118-MG	NG[5NFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV:2S2NsUUN3ME2yOk4xQDB6IN88US=>	NX\rWXFrW0GQR1XS
NB10	M2nDWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDm[45KSzVyPUK2MlI{PCEQvF2=	NW\idnlHW0GQR1XS
SK-LMS-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTJ5LkC3NFQh\|ryP	NF\rNZpUSU6JRWK=
SW1573	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LIPWlEPTB;MkeuNVEh\|ryP	M4TxdXNCVkeHUh?=
LB373-MEL-D	NEKyUlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTJ5LkGyPVQh\|ryP	M{LKcHNCVkeHUh?=
DK-MG	M2DzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoP2TWM2OD1{Nz6xPFE4KM7:TR?=	MWTTRW5ITVJ?
RMG-I	NVO2XmJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXCb2dVUUN3ME2yO{4zODJ7IN88US=>	MofxV2FPT0WU
SW1088	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTJ5LkWwOFIh\|ryP	MXLTRW5ITVJ?
SK-OV-3	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHwTWM2OD1{Nz63OVk{KM7:TR?=	MnyyV2FPT0WU
KP-N-YN	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXxR25KSzVyPUK3MlgxPDNizszN	MUfTRW5ITVJ?
RPMI-7951	NGm5PJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\hU29KSzVyPUK4MlI1PTZizszN	NF7UdoVUSU6JRWK=
CaR-1	M1vyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHn4SHVKSzVyPUK4MlU2QDJizszN	NED6RVNUSU6JRWK=
MKN7	NXLXTZh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvKTWM2OD1{OD61PVY1KM7:TR?=	MoL1V2FPT0WU
CHP-212	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\jcI5KSzVyPUK4Mlc1ODFizszN	NY\veVN1W0GQR1XS
KYSE-450	M4L3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTsTWM2OD1{OD64NFkyKM7:TR?=	NGfZXnFUSU6JRWK=
RXF393	M1TWemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnq4TWM2OD1{OT6yPVA3KM7:TR?=	NH76XI1USU6JRWK=
P30-OHK	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjCRY9DUUN3ME2yPU4{ODR6IN88US=>	NGTNUVVUSU6JRWK=
Ca9-22	NV3VTW8yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHoU3ZsUUN3ME2yPU41Ojl7IN88US=>	MYHTRW5ITVJ?
RT-112	NVX1c4tqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTJ7LkS2NVEh\|ryP	M4i2NXNCVkeHUh?=
ES1	NUnrS\|NZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NID0UHJKSzVyPUK5Mlg2PDRizszN	Ml\KV2FPT0WU
HCE-4	NHKyNIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXGyNHAxUUN3ME2yPU45Pzh4IN88US=>	NV:1WHB5W0GQR1XS
AM-38	M2D2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfPcVdLUUN3ME2zNE4xPjB4IN88US=>	NELqZ4RUSU6JRWK=
AsPC-1	M1rz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTNyLkiwOVMh\|ryP	NHLzeZZUSU6JRWK=
TE-9	MlHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;HTWM2OD1\|MD64O\|M4KM7:TR?=	NEm0V\|ZUSU6JRWK=
HuP-T4	NIK0OGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDiTWM2OD1\|MD65OlM5KM7:TR?=	MmL3V2FPT0WU
LB2518-MEL	Mn3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDBd3RTUUN3ME2zNU4xPzR2IN88US=>	NX\iWWtIW0GQR1XS
NCI-H1703	Mk\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPqWHgxUUN3ME2zNU4xQTB3IN88US=>	NXL3d5hjW0GQR1XS
NCI-H2228	M{myUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTNzLkS2OVEh\|ryP	MYjTRW5ITVJ?
SCC-4	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTNzLkmxPFEh\|ryP	MYfTRW5ITVJ?
KNS-81-FD	MlXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XN[mlEPTB;M{KuNFEzQCEQvF2=	M2HRcHNCVkeHUh?=
NTERA-S-cl-D1	M3zBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjoeGUxUUN3ME2zNk4xPzN7IN88US=>	NXHvfXdMW0GQR1XS
Daoy	MlLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVK0c5BJUUN3ME2zNk4xQDN6IN88US=>	MXjTRW5ITVJ?
ES4	NXvIVmxmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{X5VmlEPTB;M{KuN\|kzOiEQvF2=	MlHSV2FPT0WU
MHH-ES-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXT4emx2UUN3ME2zNk41QDd{IN88US=>	NIWz[mxUSU6JRWK=
C-33-A	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHq2SXZKSzVyPUOyMlc4OjhizszN	M4nyT3NCVkeHUh?=
BHY	NE\1fYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTN{Lkm0PVUh\|ryP	NHzNfoRUSU6JRWK=
Detroit562	Mn;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDYTWM2OD1\|Mz62OlU4KM7:TR?=	MVLTRW5ITVJ?
EW-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DsVmlEPTB;M{OuPVMzOiEQvF2=	M4H2UnNCVkeHUh?=
NCI-H1395	M3\FS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrYTWM2OD1\|ND6wO\|k6KM7:TR?=	M4fMc3NCVkeHUh?=
KM-H2	M2PlSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX[4VllzUUN3ME2zOk41PzR\|IN88US=>	NGPNRWxUSU6JRWK=
NCI-H520	NW\yPHJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjpTYxKSzVyPUO2Mlc2PDFizszN	NEjkVXRUSU6JRWK=
D-392MG	NX;oeI8{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DVZ2lEPTB;M{euN\|M1PCEQvF2=	MXzTRW5ITVJ?
NOMO-1	NU\mSWNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHkZYVKSzVyPUO3MlgxQDlizszN	NVO3[3pFW0GQR1XS
TE-6	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVz1V25kUUN3ME2zPE4yOjRizszN	MW\TRW5ITVJ?
HT-3	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXZXmRKSzVyPUO4MlQ1OzZizszN	MmSwV2FPT0WU
RPMI-8226	M3fV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NED6VVNKSzVyPUO4Mlk2OTlizszN	MlzjV2FPT0WU
U251	NHyyTIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXaTWM2OD1\|OT6wNVI1KM7:TR?=	M4HSTXNCVkeHUh?=
GCT	M2TSTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTN7LkG4OVIh\|ryP	MVHTRW5ITVJ?
A431	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7pTWM2OD1\|OT6xPFk1KM7:TR?=	M1X2d3NCVkeHUh?=
TE-12	NEGy[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PMeWlEPTB;M{muNlQ1QCEQvF2=	M3HLZ3NCVkeHUh?=
HMV-II	NHHqPVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\4eGlEPTB;M{muOVA1PyEQvF2=	M4XnbnNCVkeHUh?=
IST-MES1	M1vKN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHWfHM3UUN3ME20NE4yPTB{IN88US=>	NX7HR3U4W0GQR1XS
SW13	NXHSVm9vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTRyLkWxPUDPxE1?	NGTqb5BUSU6JRWK=
SF295	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoH3TWM2OD12MD64NFY3KM7:TR?=	M4fVPXNCVkeHUh?=
MDA-MB-157	M{nXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTRyLkm0OlIh\|ryP	NHSxfYpUSU6JRWK=
TE-1	NV\MRXlvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTRzLki3NVQh\|ryP	NEf6OIJUSU6JRWK=
HuCCT1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTR{LkWyPFkh\|ryP	Mn\uV2FPT0WU
KYSE-510	M{\PWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTR\|LkG3OVQh\|ryP	M3nn[XNCVkeHUh?=
NCI-H358	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLDRYFCUUN3ME20OE4xOzB2IN88US=>	M4rlSnNCVkeHUh?=
SW900	NUHHWmdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrFTohKSzVyPUS0MlA4PThizszN	MoDtV2FPT0WU
CAS-1	NYnxd5VUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHETWM2OD12ND6wPVkyKM7:TR?=	M3H4b3NCVkeHUh?=
TE-8	MkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvaPHhKSzVyPUS0MlU3PThizszN	NXfKe4dXW0GQR1XS
P12-ICHIKAWA	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF25VmlKSzVyPUS0MlYyOTJizszN	NV;GWWdyW0GQR1XS
YKG-1	MmfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVOx[pc{UUN3ME20OE44QDFizszN	NF\0ZpdUSU6JRWK=
SNU-C2B	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvzcJFKSzVyPUS0Mlc6ODNizszN	NGfTWXpUSU6JRWK=
LCLC-103H	M1v0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTR2Lki3NFMh\|ryP	NHPMeGZUSU6JRWK=
U-87-MG	M{W1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF63SHhKSzVyPUS1MlExOjJizszN	Mn;BV2FPT0WU
HAL-01	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTaNZVUUUN3ME20OU4yOzd7IN88US=>	NET5SFFUSU6JRWK=
OVCAR-8	NWDhTmZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\ETWM2OD12NT6zOVY1KM7:TR?=	MnrpV2FPT0WU
KYSE-150	NHm5cYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTR5LkGwOVIh\|ryP	NXTmN21jW0GQR1XS
OE33	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;DOWlEPTB;NEeuNVQzQSEQvF2=	M2X5OnNCVkeHUh?=
CAL-62	NGL0VINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTR5LkSwOlgh\|ryP	MortV2FPT0WU
TCCSUP	NHfhUnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTR5Lk[yOlQh\|ryP	MoT6V2FPT0WU
H4	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIj2cFNKSzVyPUS3MlY3OjFizszN	NHnOZVFUSU6JRWK=
CP66-MEL	MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHITI9KSzVyPUS4MlA4ODRizszN	NF;uNpNUSU6JRWK=
SNB75	NHTRb2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmmwTWM2OD12OD6xPFc1KM7:TR?=	MlfMV2FPT0WU
Mo-T	MmKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljaTWM2OD12OD6yO\|kh\|ryP	MXrTRW5ITVJ?
BT-549	NV;QS2FpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7Wcm11UUN3ME20PE4{PzJ7IN88US=>	NX;mXVVVW0GQR1XS
IGR-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvJTWM2OD12OD62OlQ2KM7:TR?=	NGLUPY1USU6JRWK=
NCI-H1299	NGHZOWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnOTWM2OD12OD63NlQ5KM7:TR?=	MoPvV2FPT0WU
ALL-PO	MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnMO5BKSzVyPUS5MlkzPjhizszN	NX\4[JZpW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-DNA-PKcs / DNA-PKcs / p-ATM / ATM / p-ATR / ATR / Ku70 / p-CHK1 / p-CHK2/ p-AKT / RAD51; PubMed: 29344644 Oncol Rep SUNE1 cells were irradiated with 5 Gy in the presence or absence of NU7441 (2 µM). The expression of cell cycle checkpoint proteins and double strand break repair proteins was assayed by western blot analysis at 6 or 12 h post-IR. p-mTOR(Ser2448) / mTOR / p-S6K(Thr389); PubMed: 25714019 Oncotarget Phosphorylation of mTOR and p70S6K were detected by Western blot analysis 24 hours after treatment.	29344644 25714019

In vivo

NU7441 intraperitoneally administrated at dose of 10 mg/kg maintains for at least 4 hours shows nontoxic and increases etoposide-induced tumor growth delay 2-fold in mice bearing SW620 xenografts. ^[2]

Protocol

Cell Research: ^[2]	- Collapse Cell lines: SW620, LoVo, V3-YAC and V3 cells Concentrations: 0.5 μM or 1 μM Incubation Time: 17 hours Method: The effect of NU7441 on cellular survival following exposure to etoposide, doxorubicin, and ionizing radiation is measured in SW620, LoVo, V3, and V3-YAC cells by clonogenic assays. Briefly, growing cells in six-well plates or 6-cm dishes are exposed to etoposide or doxorubicin with or without NU7441 (0.5 or 1.0 μM) for 16 hours. For radiosensitization studies, NU7441 is added to the cells 1 hour before irradiation. V3 and V3-YAC cells are exposed to γ-irradiation (3.1 Gy/min ¹³⁷Cesium). SW620 and LoVo are exposed to X-irradiation (2.9 Gy/min at 230 kV, 10 mA) due to the equipment available. After irradiation, the cells are incubated with or without NU7441 for a further 16 hours. Cells are then harvested by trypsinization, counted, and seeded into 10-cm diameter Petri dishes at densities varying from 100 to 10⁵ per dish in drug-free medium for colony formation. Colonies are stained with crystal violet after 10 to 14 days and counted with an automated colony counter. The survival reduction factor (SRF) is calculated as the surviving fraction of cells in the absence of NU7441 divided by the surviving fraction of cells in the presence of NU7441 for any given dose or concentration of cytotoxic agent. The dose modification ratio (DMR90) is calculated as the concentration/dose of cytotoxic agent required to kill 90% of the cells in the absence of NU7441 divided by the concentration/dose of cytotoxic agent required to kill 90% of the cells in the presence of NU7441. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: Female rude mice bearing SW620 xenografts Formulation: Sterile 0.9% sodium chloride solution Dosages: 10 mg/kg Administration: Intraperitoneally administrated (Only for Reference)

Cell Research:

^[2]

- Collapse

Cell lines: SW620, LoVo, V3-YAC and V3 cells
Concentrations: 0.5 μM or 1 μM
Incubation Time: 17 hours
Method:
The effect of NU7441 on cellular survival following exposure to etoposide, doxorubicin, and ionizing radiation is measured in SW620, LoVo, V3, and V3-YAC cells by clonogenic assays. Briefly, growing cells in six-well plates or 6-cm dishes are exposed to etoposide or doxorubicin with or without NU7441 (0.5 or 1.0 μM) for 16 hours. For radiosensitization studies, NU7441 is added to the cells 1 hour before irradiation. V3 and V3-YAC cells are exposed to γ-irradiation (3.1 Gy/min ¹³⁷Cesium). SW620 and LoVo are exposed to X-irradiation (2.9 Gy/min at 230 kV, 10 mA) due to the equipment available. After irradiation, the cells are incubated with or without NU7441 for a further 16 hours. Cells are then harvested by trypsinization, counted, and seeded into 10-cm diameter Petri dishes at densities varying from 100 to 10⁵ per dish in drug-free medium for colony formation. Colonies are stained with crystal violet after 10 to 14 days and counted with an automated colony counter. The survival reduction factor (SRF) is calculated as the surviving fraction of cells in the absence of NU7441 divided by the surviving fraction of cells in the presence of NU7441 for any given dose or concentration of cytotoxic agent. The dose modification ratio (DMR90) is calculated as the concentration/dose of cytotoxic agent required to kill 90% of the cells in the absence of NU7441 divided by the concentration/dose of cytotoxic agent required to kill 90% of the cells in the presence of NU7441.

(Only for Reference)

Animal Research:

^[2]

- Collapse

Animal Models: Female rude mice bearing SW620 xenografts
Formulation: Sterile 0.9% sodium chloride solution
Dosages: 10 mg/kg
Administration: Intraperitoneally administrated
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	4 mg/mL warmed (9.67 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download NU7441 (KU-57788) SDF

Molecular Weight	413.49
Formula	C₂₅H₁₉NO₃S
CAS No.	503468-95-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Could you please suggest formulations of the drug for in vivo injection?
Answer:
We tested the following formulation for in vivo use, 4% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 1mg/mL. It is a clear solution.
Question 2:
Previous aliquots were clear and colorless while this time, it becomes yellow when the powder was dissolved in DMSO? Could you advice on this?
Answer:
Slight color variation due to different processing is normal and usually doesn't interfere with the function.

DNA-PK Signaling Pathway Map

DNA-PK Inhibitors with Unique Features

Non-specific DNA-PK Inhibitor

PI-103 : DNA-PK, IC50=23 nM; p110α/β/δ/γ, IC50=2 nM/3 nM/3 nM/15 nM; mTOR, IC50=30 nM.
Most Potent DNA-PK Inhibitor

PIK-75 : DNA-PK, IC50=2 nM.
Newest DNA-PK Inhibitor

KU-0060648 : Dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.
Classic DNA-PK Inhibitor

NU7026 : Potent DNA-PK inhibitor with IC50 of 0.23 μM, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.

Related DNA-PK Products

CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
NU7026

NU7026 is a potent DNA-PK inhibitor with IC50 of 0.23 μM in cell-free assays, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.
KU-0060648

KU-0060648 is a dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
CHIR-99021 (CT99021) HCl

CHIR-99021 HCl (CT99021) is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.

Choose Your Country or Region

By Signaling Pathways

By product type

NU7441 (KU-57788)

Cited by 86 Publications

Purity & Quality Control

Choose Selective DNA-PK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download NU7441 (KU-57788) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

DNA-PK Signaling Pathway Map

DNA-PK Inhibitors with Unique Features

Related DNA-PK Products

Choose Your Country or Region

By Signaling Pathways

By product type

NU7441 (KU-57788)

Cited by 86 Publications

Purity & Quality Control

Choose Selective DNA-PK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download NU7441 (KU-57788) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

DNA-PK Signaling Pathway Map

DNA-PK Inhibitors with Unique Features

Related DNA-PK Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)